Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Impedimed Limited ( (AU:IPD) ) has provided an announcement.
Impedimed Limited announced a change in the director’s interest, specifically involving Ms. Christine Emmanuel-Donnelly. The change was due to an issue of shares in lieu of 30% of director fees for the quarter ended 31 December 2024, resulting in Ms. Emmanuel-Donnelly acquiring additional shares indirectly through the Donnelly Family Trust. This move could indicate strategic financial planning by the company, potentially impacting stakeholder confidence and the company’s operational dynamics.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, providing services primarily focused on bioimpedance spectroscopy (BIS) technology. The company specializes in non-invasive medical devices that are used for the detection and monitoring of fluid status and tissue composition, targeting applications in healthcare sectors such as oncology, heart failure, and renal failure.
YTD Price Performance: -2.50%
Average Trading Volume: 31,879
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $69.19M
For detailed information about IPD stock, go to TipRanks’ Stock Analysis page.
